4925 — Haba Laboratories Income Statement
0.000.00%
Last trade - 00:00
- ¥8bn
- ¥6bn
- ¥12bn
- 51
- 46
- 23
- 31
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 18,370 | 14,308 | 12,909 | 12,038 | 12,324 |
Cost of Revenue | |||||
Gross Profit | 13,664 | 10,200 | 8,795 | 8,169 | 8,404 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 16,416 | 14,073 | 13,202 | 12,623 | 14,160 |
Operating Profit | 1,954 | 235 | -293 | -585 | -1,836 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,928 | 284 | -267 | -549 | -1,843 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,313 | 216 | -269 | -708 | -2,119 |
Net Income Before Extraordinary Items | |||||
Net Income | 1,313 | 216 | -269 | -708 | -2,119 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,313 | 216 | -269 | -708 | -2,119 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 348 | 50.5 | -75.5 | -193 | -276 |
Dividends per Share |